Cover Image
市場調查報告書

神經母細胞瘤:開發平台分析

Neuroblastoma - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 229754
出版日期 內容資訊 英文 417 Pages
訂單完成後即時交付
價格
Back to Top
神經母細胞瘤:開發平台分析 Neuroblastoma - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 417 Pages
簡介

所謂神經母細胞瘤是腎上腺、頸部、胸部、脊椎的神經組織、神經脊細胞產生的癌,大部分患者都是嬰幼兒。一般是發生在腎上腺,之後轉移到人體其他部位。容易罹病的危險因子包含了遺傳。主要的症狀有腹部·胸部的腫塊,及噁心、骨骼疼痛、呼吸困難、黑眼圈、移動困難等。診斷時常用到X光掃描影像檢查和電腦斷層掃描、核磁共振攝影、切片檢查、尿液檢查等。使用化療和放射治療、幹細胞移植、單株抗體等醫藥療法有控制病情的可能性。

本報告提供全球各國治療神經母細胞瘤(Neuroblastoma)所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

神經母細胞瘤概要

治療藥的開發

  • 神經母細胞瘤開發中產品:概要
  • 神經母細胞瘤開發中產品:比較分析

各企業開發中的神經母細胞瘤治療藥

大學/研究機關研究中的神經母細胞瘤治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

神經母細胞瘤治療藥:開發中的產品一覽(各企業)

神經母細胞瘤治療藥:研究中的產品一覽(各大學/研究機關)

神經母細胞瘤治療藥的開發企業

  • Ability Pharmaceuticals, S.L.
  • Acetylon Pharmaceuticals, Inc.
  • Advanced Accelerator Applications S.A.
  • Ampio Pharmaceuticals, Inc.
  • APEIRON Biologics AG
  • AstraZeneca Plc
  • Bellicum Pharmaceuticals, Inc.
  • Bexion Pharmaceuticals, LLC. .
  • BioLineRx, Ltd.
  • Bionucleon Srl
  • Biotec Pharmacon ASA
  • Cebiotex, S.L.
  • Celgene Corporation
  • 中外製藥
  • Cleveland BioLabs, Inc.
  • CorMedix Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • DEKK-TEC, Inc.
  • EnGeneIC Ltd
  • Errant Gene Therapeutics, LLC
  • GlaxoSmithKline Plc
  • Green Cross Cell Corporation
  • Ignyta, Inc.
  • Incuron, LLC
  • Juno Therapeutics Inc.
  • Kolltan Pharmaceuticals, Inc.
  • Lindis Biotech GmbH
  • MabVax Therapeutics Holdings, Inc
  • MediaPharma s.r.l.
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Morphogenesis, Inc.
  • Novartis AG
  • Novogen Limited
  • Pfizer Inc.
  • Pharmacyclics, Inc.
  • Progenics Pharmaceuticals, Inc.
  • Recombio S.L
  • Ribomic Inc.
  • Sareum Holdings Plc
  • 鹽野義製藥
  • Syros Pharmaceuticals, Inc.
  • Threshold Pharmaceuticals, Inc.
  • Tiltan Pharma Ltd.

神經母細胞瘤:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

神經母細胞瘤治療藥:開發中產品的最新趨勢

神經母細胞瘤治療藥:暫停開發的產品

神經母細胞瘤治療藥:中止開發的產品

神經母細胞瘤相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9391IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Pipeline Review, H1 2017, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.

Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 20, 19, 1, 44, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 6, 13 and 3 molecules, respectively.

Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • Introduction 5
  • Neuroblastoma - Overview 6
  • Neuroblastoma - Therapeutics Development 7
  • Neuroblastoma - Therapeutics Assessment 23
  • Neuroblastoma - Companies Involved in Therapeutics Development 37
  • Neuroblastoma - Drug Profiles 64
  • Neuroblastoma - Dormant Projects 390
  • Neuroblastoma - Discontinued Products 393
  • Neuroblastoma - Product Development Milestones 394
  • Appendix 404

List of Tables

  • Number of Products under Development for Neuroblastoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Neuroblastoma - Pipeline by Ability Pharmaceuticals SL, H1 2017
  • Neuroblastoma - Pipeline by Actuate Therapeutics Inc, H1 2017
  • Neuroblastoma - Pipeline by Advanced Accelerator Applications SA, H1 2017
  • Neuroblastoma - Pipeline by Alissa Pharma, H1 2017
  • Neuroblastoma - Pipeline by Ampio Pharmaceuticals Inc, H1 2017
  • Neuroblastoma - Pipeline by APAvadis Biotechnologies Srl, H1 2017
  • Neuroblastoma - Pipeline by APEIRON Biologics AG, H1 2017
  • Neuroblastoma - Pipeline by AstraZeneca Plc, H1 2017
  • Neuroblastoma - Pipeline by Bayer AG, H1 2017
  • Neuroblastoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
  • Neuroblastoma - Pipeline by Bexion Pharmaceuticals LLC, H1 2017
  • Neuroblastoma - Pipeline by BioLineRx Ltd, H1 2017
  • Neuroblastoma - Pipeline by Biotec Pharmacon ASA, H1 2017
  • Neuroblastoma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Neuroblastoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Neuroblastoma - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2017
  • Neuroblastoma - Pipeline by Cebiotex SL, H1 2017
  • Neuroblastoma - Pipeline by Celgene Corp, H1 2017
  • Neuroblastoma - Pipeline by Celldex Therapeutics Inc, H1 2017
  • Neuroblastoma - Pipeline by Cielo Therapeutics Inc, H1 2017
  • Neuroblastoma - Pipeline by Cleveland BioLabs Inc, H1 2017
  • Neuroblastoma - Pipeline by CorMedix Inc, H1 2017
  • Neuroblastoma - Pipeline by Curis Inc, H1 2017
  • Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
  • Neuroblastoma - Pipeline by DEKK-TEC Inc, H1 2017
  • Neuroblastoma - Pipeline by EnGeneIC Ltd, H1 2017
  • Neuroblastoma - Pipeline by Errant Gene Therapeutics LLC, H1 2017
  • Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Neuroblastoma - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Neuroblastoma - Pipeline by Green Cross Cell Corp, H1 2017
  • Neuroblastoma - Pipeline by Ignyta Inc, H1 2017
  • Neuroblastoma - Pipeline by Juno Therapeutics Inc, H1 2017
  • Neuroblastoma - Pipeline by Lindis Biotech GmbH, H1 2017
  • Neuroblastoma - Pipeline by MabVax Therapeutics Holdings Inc, H1 2017
  • Neuroblastoma - Pipeline by MacroGenics Inc, H1 2017
  • Neuroblastoma - Pipeline by MediaPharma srl, H1 2017
  • Neuroblastoma - Pipeline by Merck & Co Inc, H1 2017
  • Neuroblastoma - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
  • Neuroblastoma - Pipeline by Morphogenesis Inc, H1 2017
  • Neuroblastoma - Pipeline by Novartis AG, H1 2017
  • Neuroblastoma - Pipeline by Novogen Ltd, H1 2017
  • Neuroblastoma - Pipeline by OGD2 Pharma SAS, H1 2017
  • Neuroblastoma - Pipeline by Pfizer Inc, H1 2017
  • Neuroblastoma - Pipeline by Phylogica Ltd, H1 2017
  • Neuroblastoma - Pipeline by Progenics Pharmaceuticals Inc, H1 2017
  • Neuroblastoma - Pipeline by Recombio SL, H1 2017
  • Neuroblastoma - Pipeline by Ribomic Inc, H1 2017
  • Neuroblastoma - Pipeline by Sapience Therapeutics Inc, H1 2017
  • Neuroblastoma - Pipeline by Sareum Holdings Plc, H1 2017
  • Neuroblastoma - Pipeline by Shionogi & Co Ltd, H1 2017
  • Neuroblastoma - Pipeline by Sierra Oncology Inc, H1 2017
  • Neuroblastoma - Pipeline by Syros Pharmaceuticals Inc, H1 2017
  • Neuroblastoma - Pipeline by Tiltan Pharma Ltd, H1 2017
  • Neuroblastoma - Pipeline by Trovagene Inc, H1 2017
  • Neuroblastoma - Dormant Projects, H1 2017
  • Neuroblastoma - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Neuroblastoma - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Neuroblastoma - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Neuroblastoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top